BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Benitec Biopharma Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026
$8.36+0.25 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $413.29M
- P/E (TTM)
- –
- Dividend yield
- –
Benitec Biopharma Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Licensing revenue [Member] | $0 | $75.00K | $73.00K | $59.00K | $0 | $10.27M | – | -100.0% |
| Service revenue [Member] | – | – | – | $0 | $4.00K | $1.10M | – | – |
| Royalty revenue [Member] | – | – | – | $0 | $93.00K | $183.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Benitec Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.